Document Detail


Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
MedLine Citation:
PMID:  6749279     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Seventy-five patients with diffuse histiocytic lymphoma (DHL) ranging in age from 33 to 94 years were treated with cyclophosphamide, Adriamycin, vincristine and prednisone (CHOP). Thirty-eight patients (51%) achieved complete remission, but nine of these patients relapsed after remission lasting one to 23 months (median time to relapse, four months). We used multivariate analysis to identify those characteristics that significantly affected treatment outcome. The chances for complete remission were adversely affected by DHL appearing after histologic conversion from another lymphoma (P = 0.006), the presence of systemic symptoms (P = 0.24), and not having the large noncleaved (LNC) histologic subtype (P = 0.40). The chance for relapse from complete remission was increased only by the presence of systemic symptoms (P = 0.042). Overall survival was adversely affected by the presence of bone marrow involvement (P = 0.002), having other than LNC histologic subtype (P = .010), and the presence of systemic symptoms (P = 0.043). It appears that patients whose DHL appears de novo and who also are symptom status A (70% long-term disease-free survival) or have the LNC histologic subtype (67% long-term disease-free survival) have an excellent outlook when treated with CHOP at the doses used in this study. However, patients with B symptoms (16% long-term disease-free survival), histologic conversion to DHL (8% long-term disease-free survival), previous chemotherapy (8% long-term disease-free survival), and bone marrow involvement (8% long-term disease-free survival) respond poorly and for these patients other treatments need to be identified. In addition, patients with B symptoms who achieve complete remission with CHOP are at high risk to relapse (59% relapse rate) and should be considered for "intensification" therapy after complete remission is documented.
Authors:
J O Armitage; F R Dick; M P Corder; S C Garneau; C E Platz; D J Slymen
Related Documents :
8522489 - Experimental therapies in the treatment of cutaneous t-cell lymphoma.
17453819 - A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult...
6992679 - Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (com...
16109619 - Very good partial response in a patient with malt-lymphoma of the lung after treatment ...
15085149 - Prognostic significance of molecular staging by pcr-amplification of immunoglobulin gen...
11464129 - Primary lymphoma of the epididymis: case report and review of the literature.
3297289 - Strategies for the management of recurrent and advanced urologic cancers. quality of life.
16912909 - Value of intraoperative radiotherapy in locally advanced rectal cancer.
21429739 - Vegf-spect with ¹¹¹in-bevacizumab in stage iii/iv melanoma patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  50     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1982 Nov 
Date Detail:
Created Date:  1982-12-03     Completed Date:  1982-12-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1695-702     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Analysis of Variance
Antineoplastic Agents / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols*
Bone Marrow / pathology
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Drug Therapy, Combination
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*,  pathology
Male
Middle Aged
Neoplasm Staging
Prednisone / administration & dosage
Prognosis
Vincristine / administration & dosage
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/CHOP protocol; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carcinoembryonic antigen in sweat-gland carcinomas.
Next Document:  Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma ...